Project Grant R43AG090243
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$350K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $429,000.00 to the University of Texas Health Science Center at Houston to conduct research on the connection between Alzheimer's disease pathogenesis and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. The key objectives are to: 1) Evaluate anxiety-related behavioral and endocrine changes resulting from selective expression of Alzheimer's-linked amyloid precursor protein...
This $3,357,206 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) aims to develop a novel disease-modifying compound for the treatment of Alzheimer's disease (AD). The funding supports a clinical evaluation of the small molecule compound BMS-984923, which has demonstrated efficacy in preclinical mouse models of AD. The key objectives are to evaluate the safety, tolerability, and receptor occupancy of BMS-984923 in Phase 1 clinical...
This federal Project Grant award for $500,000, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports the development of a novel, multi-target peptide drug called ALZ100 for the treatment of Alzheimer's disease (AD). The grantee, Alzarrok Bio LLC, is conducting in vivo studies in an AD mouse model to demonstrate ALZ100's ability to inhibit key disease drivers, including amyloid-beta oligomers, the RAGE and TLR4 receptors, and the S100A9 protein. The goal is to show...
This $949,062 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Somatoceutics LLC aims to develop a novel, non-toxic nanomaterial for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and related dementias. The key objectives are to: Optimize and standardize the assembly of SMC-101 nanotubes, a natural peptide-based nanomaterial, to load with drugs and demonstrate their ability to transcytose the blood-brain barrier in vitro....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of novel, brain-penetrant drugs for Alzheimer's disease therapeutics. The $994,436 award to Transchromix LLC, located in Chapel Hill, NC, funds research to investigate the role of the histone methyltransferase G9A in Alzheimer's disease pathogenesis. The project aims to elucidate the non-canonical, translation regulatory function of G9A and evaluate the mechanism of action for...
This $504,732 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The awardee, Aphios Corp, will (1) nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, and (2) evaluate the impact of the nanoparticles on in vitro models of brain inflammation and blood-brain barrier penetration. The project aims to identify optimal nanoparticle candidates...
The National Institute on Aging (NIA) awarded a $514,862 Project Grant (CFDA 93.866 - Aging Research) to Neuroindx, a for-profit, woman-owned small business, to develop an on-chip functional assay for identifying candidate microtubule-binding drugs to treat Alzheimer's Disease and related disorders (ADRDs). The project aims to create an in vitro, cell-free assay that can replicate key features of the neuronal microtubule microenvironment and use a kinesin-based readout system to measure the...
The U.S. National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $3,474,488 Cooperative Agreement to Emory University to develop a small-molecule antagonist of the EP2 receptor as a potential treatment for Alzheimer's disease (AD). The project aims to define the pharmacokinetic and pharmacodynamic relationships of the EP2 antagonist lead candidates on AD pathology markers in the brain, as well as on relevant biomarkers in the blood,...
This $1,758,779 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research by the Winifred Masterson Burke Medical Research Institute to assess neuronal vulnerability in the entorhinal cortex due to Alzheimer's disease pathology. The key objectives are to determine whether hyperexcitability in Alzheimer's disease is caused by dysfunction of excitatory or inhibitory neurons in the entorhinal cortex, and to modulate neuronal activities to...
The National Institute on Aging (NIA) awarded a $4,618,216 Cooperative Agreement (U01AG088051) to the University of California, San Diego (UCSD) to develop a microtubule-stabilizing agent, CNDR-51997, for the treatment of Alzheimer's disease and related tauopathies. The project aims to conduct IND-enabling studies and submit an Investigational New Drug (IND) application for this novel compound to the FDA. As part of the effort, UCSD is collaborating with a sub-awardee, the Trustees of the...